VivoSim Labs Partners With Chemveda Life Sciences To Test, Screen AI-Derived Drug Compounds In VivoSim's NAMkind 3D Tissue Models

VivoSim Labs, Inc. (Nasdaq: VIVS) ("VivoSim" or "Company"), a provider of AI-enabled New Approach Methodologies (NAMs) for preclinical safety, and Chemveda Life Sciences ("Chemveda"), an integrated contract research, development and manufacturing organization (CRDMO), today announced a strategic collaboration to test and screen AI-derived drug compounds in VivoSim’s human-relevant NAMkind™ 3D tissue models.

Under the collaboration, Chemveda will support the design, synthesis, optimization and development of AI-designed compounds for pharmaceutical and biotechnology clients, while VivoSim will evaluate selected compounds using its NAMkind™ Liver and NAMkind™ Intestine human tissue models, built from primary human cells. The result is a rapid design-make-test cycle in which toxicity and efficacy signals from human tissue reach the chemist while the molecule can still be changed. VivoSim’s prospective screens can evaluate more than 20 compounds in two weeks.